Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:58:07 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Ascelia Pharma - All attention on the top priority

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Ascelia Pharma - All attention on the top priority

2023-09-18 08:20:00

Ascelias priority is to secure a re-reader evaluation of SPARKLE by May 2024. This involves minimising the risk of eccessive intra reader variability. The time table is realistic but the risk for delays are never zero. Our base case in now a US partner strategy which could bring several advantages in our view. Our update includes a base case valuation of SEK 10 (11) and a Bull Case of SEK 26 (28), and a Bear Case of SEK 3 (3).

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/